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Abstract 
Background: Previous studies have indicated that enhancement of autophagy lysosome pathway may be beneficial 
for Parkinson’s disease (PD), in which aberrant accumulation of aggregated/misfolded proteins and mitochondrial 
dysfunction are considered as crucial pathogenesis. Recently, a number of studies have suggested the neuroprotec-
tive effects of lithium in models of several neurodegenerative diseases including PD. However, the exact mechanisms 
underlying this neuroprotection remain unclear. In our study, rotenone-exposed SH-SY5Y cells were used as an 
in vitro parkinsonian model to assess the autophagy-enhancing effect of lithium and the underlying mechanisms 
were further investigated.
Results: Similar to the common used autophagy enhancer rapamycin (Rap, 0.2 μM), lithium (LiCl, 10 mM) signifi-
cantly recovered the shrinkage of SH-SY5Y cells, and alleviated rotenone-induced cell apoptosis, mitochondrial 
membrane potential reduction and reactive oxygen species accumulation. Furthermore, the protective effects 
induced by LiCl were partially blocked by the co-treatment of autophagy inhibitors such as 3-methyladenine (3-MA, 
10 mM) or chloroquine (CHL, 10 μM). Moreover, 3-MA or Chl suppressed LiCl-induced autophagy in the immunob-
lot assay. In addition, the co-localization of LC3 and mitochondria and the preservation of mitochondrial function 
within LiCl-treated cells were observed, confirming that the damaged mitochondria were cleared through autophagy 
(mitophagy).
Conclusions: These findings suggested that lithium exerted neuroprotection against rotenone-induced injuries par-
tially through the autophagy pathway. Pharmacologically induction of autophagy by lithium may represent a novel 
therapeutic strategy as a disease-modifier in PD.
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Background
Parkinson’s disease (PD), a chronic and progressive neu-
rodegenerative disease, is manifested as motor symptoms 
such as tremor, bradykinesia, rigidity and postural insta-
bility, as well as non-motor symptoms such as depres-
sion, apathy, sleep disorders and erectile dysfunction 
[1]. The hallmark pathological signs of PD include the 
degeneration of dopaminergic (DA) neurons in the sub-
stantia nigra and the formation of α-synuclein+ protein 
aggregates which are called Lewy bodies or Lewy neur-
ites in the remaining DA neurons. Although treatments 
that slow or halt the disease process are currently una-
vailable, manipulating protein aggregation seems to have 
great potential for disease-modification [1].
There are two important mechanisms for protein deg-
radation in the mammal cells, detailed as the autophagy-
lysosome pathway (ALP) and the ubiquitin-proteasome 
system (UPS). Previous studies have demonstrated that 
dysfunction of these two systems plays vital roles in 
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the pathogenesis of PD [2–5]. The function of UPS is 
limited by the core volume, and upregulated protea-
some activity only leads to non-selective degradation 
of key short-lived intracellular regulators, resulting in 
detrimental consequences, such as cancer in the case 
of tumor suppressor p53 [1]. In contrast, ALP degrades 
entire organelles such as mitochondria and large mem-
brane proteins which fail to recycle by UPS [4, 6]. Thus, 
enhancement of autophagy might be a novel strategy for 
the treatment of protein accumulation-related diseases, 
such as PD.
The commonly used strategy for inducing autophagy 
is employing rapamycin, an inhibitor of the mammalian 
target of rapamycin (mTOR) [7, 8]. Previous studies have 
revealed that rapamycin exerts neuroprotective effects 
in several models of neurodegenerative diseases such 
as Alzheimer’s disease (AD) and PD through autophagy 
enhancement [9–11]. However, since mTOR plays an 
important role in regulating a variety of basic cellular 
processes, long-term use of rapamycin may cause some 
deleterious consequences, including cell over-growth and 
proliferation [12]. It is crucial to explore an autophagy 
enhancer which is safe, clinical-relevant and easy to 
administrate.
Unlike rapamycin, lithium (LiCl) induces autophagy 
via an mTOR-independent pathway. By inhibiting the 
inositol monophosphatase (IMPase), LiCl ultimately 
results in the reduction of free inositol cellular level 
[13–16]. A recent study has indicated that LiCl sup-
pressed Aβ pathology by inhibiting the translation of 
protein in a Drosophila model of AD [17]. Further-
more, LiCl protected against paraquat-induced neu-
rotoxicity by NRF2 activation and miR-34a inhibition 
in SH-SY5Y cells [18]. Moreover, our previous studies 
have suggested that LiCl might be neuroprotective in 
rotenone-induced SH-SY5Y cells and MPTP-lesioned 
mice though autophagy enhancement [19, 20]. How-
ever, another study have indicated that LiCl was unable 
to alleviate the degeneration of DA neurons induced 
by 6-OHDA, suggesting that GSK3 was minimally 
involved in the neurodegeneration [21]. Thus, it remains 
unclear whether or not LiCl exerts neuroprotective 
effects and by which pathway LiCl is involved in the 
neuroprotection.
In this study, rotenone-exposed SH-SY5Y cells were 
used as an in  vitro model of PD, and cell viability, acti-
vation of apoptosis, oxidative stress and mitochondrial 
dysfunction were assessed respectively [3, 22, 23, 24]. 
Rapamycin was used as a positive control for induction 
of autophagy. The neuroprotective effects of LiCl on the 
rotenone-induced cellular model as well as the underly-
ing mechanisms were further explored.
Results
LiCl increased cell viability upon rotenone exposure 
in SH‑SY5Y cells
We first examined whether or not LiCl affected cell 
survival under normal culture condition. MTT analy-
sis indicated that in the range of 1 mM to 15 mM, LiCl 
did not significantly affect the viability of SH-SY5Y cells, 
while the concentration of 50  mM LiCl directly caused 
48.3  ±  5.37  % reduction of MTT absorbance. When 
treated with rotenone for 24  h, rotenone decreased 
cell viability by 67.56  % compared with control group, 
and by 37.46, 32.61, 18.32, 13.68, 23.94 and 41.21  % in 
LiCl2 +  Rot, LiCl4 +  Rot, LiCl8 +  Rot, LiCl10 +  Rot, 
LiCl15  +  Rot and LiCl50  +  Rot groups, respectively 
(Fig. 1b). LiCl with a dose range from 2 mM to 50 mM 
could alleviate rotenone-induced cell death. Moreover, 
the most significant cytoprotection of LiCl was observed 
at the concentration of 10  mM (Fig.  1b). Therefore, we 
chose the concentration of 10  mM for the subsequent 
tests.
LiCl prevented from rotenone‑induced cell injury
First, LiCl-induced neuroprotection was revealed by cell 
morphology. SH-SY5Y cells under normal culture con-
dition grew into a neuron-like phenotype with extended 
neuritis. Exposure to rotenone (200 nM) for 24 h resulted 
in shortening of neurites and shrinking of the cell bod-
ies, which was inhibited by rapamycin or LiCl pretreat-
ment (Fig. 2a). However, the rehabilitative effect of LiCl 
was partially blocked when cells were co-treatment with 
the autophagy inhibitors 3-MA or CHL. The MTT assay 
indicated that rotenone significantly decreased cell via-
bility by  ~60  %, while pretreatment with rapamycin or 
LiCl significantly attenuated the toxic effects induced by 
rotenone. (Figure  2b). Such rescue of cell viability was 
partially attenuated by simultaneously pretreatment of 
3-MA or CHL. Similar results were observed from cell 
apoptosis analysis (Fig. 3a). Rotenone exposure led to an 
increase of cell apoptosis, which was discounted by LiCl 
or rapamycin pretreatment, while the protective effect of 
LiCl was partially weakened by 3-MA or CHL, suggesting 
that the neuroprotective effect of LiCl may be related to 
autophagy induction (Fig. 3a).
LiCl protected against rotenone‑induced mitochondrial 
dysfunction
The SH-SY5Y cells in negative control showed accumu-
lation of red fluorescence and extended neurites, while 
rotenone exposure led to reduced red fluorescence with 
condensed nuclei and cell shrinkage, indicating a collapse 
of MMP with exposure to rotenone (Fig. 3c). The reduc-
tion in MMP meant a lower capacity to produce ATP. 
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Then the cells pretreated with LiCl significantly inhib-
ited the decrease of fluorescence intensity, indicating that 
LiCl prevented rotenone-induced mitochondrial injury. 
In one hand, mitochondrial dysfunction triggered ROS 
formation, on the other hand, accumulated ROS could 
in turn cause oxidative damage of mitochondria. To 
confirm the neuroprotective effect of LiCl on mitochon-
dria, we measured the levels of ROS in different groups. 
Rotenone evoked obvious production of ROS, and LiCl 
indeed alleviated the overgeneration of ROS. However, 
this protective effect of LiCl was partially attenuated 
when cells were simultaneously pretreated with 3-MA 
or CHL (Fig. 3b). In addition, pretreatment of cells with 
CHL resulted in a higher level of ROS release than the 
rotenone group, indicating that CHL increased cellu-
lar vulnerability to rotenone toxicity and mitochondrial 
dysfunction.
LiCl enhanced autophagy in SH‑SY5Y cells
In immunoblot assay, the ratio of LC3-II/I with LiCl pre-
treatment was increased by ~84 % when compared to the 
vehicle control, similar tendency to that of the rapamy-
cin, while the ratio was slightly decreased with co-treat-
ment of LiCl and 3-MA. LC3 expression was highest in 
the group with co-treatment of LiCl and CHL. By dis-
rupting the pH of acidic vesicles, CHL prevented the 
fusion process of lysosomes and autophagosomes, and 
ultimately elevated the cellular burden of autophago-
some accumulation [25]. Thus, the accumulation of 
LC3-II, a classic marker of autophagosome, suggested 
either that autophagy has been stimulated and/or that 
the maturation of autophagosomes has been blocked (in 
the case of the addition of CHL) [26]. Our immunoblot 
assay indicated that autophagy was up-regulated dur-
ing LiCl or rapamycin exposure, and such induction of 
autophagy was attenuated when cells were treated with 
3-MA or CHL simultaneously (Fig. 4), suggesting that the 
protective effect of LiCl was related to the induction of 
autophagy.
Damaged mitochondria were eliminated via autophagy
To detect the association between autophagy induc-
tion and the restored mitochondrial function, further 
immunostaining analysis without rotenone exposure 
was performed. The results showed that LiCl treatment 
contributed to a punctuate pattern of LC3 fluorescence 
in the cytoplasm of SH-SY5Y cells, while it led to a dif-
fuse distribution of LC3 in the absence of LiCl. Addition-
ally, this effect could be partially attenuated by 3-MA or 
CHL co-treatment (Fig. 5). As shown in the Fig. 5r, there 
is no statistical difference between these groups regard-
ing the normalized MitoTracker Red fluorescence in the 
cytoplasm. However, 3-MA or CHL co-treatment sig-
nificantly reduced the LC3 aggregation induced by LiCl 
(Fig.  5q). Co-localization of MitoTracker Red and LC3 
indicated that the turnover of mitochondria might be 
within autophagolysosomes.
Discussion
As a mood stabilizer, LiCl is traditionally used to treat 
bipolar disorder [27]. Recent research has focused on its 
neuroprotective potential and regarded it as a candidate 
agent for disease-modifying therapy in several neurode-
generative diseases [28–30]. The neuroprotective effect 
of LiCl may rely on autophagy induction. In our study, 
human SH-SY5Y cells exposed to rotenone were used 
Fig. 1 Lithium protected against rotenone-induced cytotoxicity in SH-SY5Y cells. Cell viability was measured by MTT assay after treatment of SH-
SY5Y cells with lithium for 24 h at indicated concentrations with or without rotenone exposure. a Lithium exposure (0–15 mM) had no negative 
influence on the cell survival of SH-SY5Y cells under normal culture condition. b Lithium dose-dependently protected SH-SY5Y cells from rotenone-
induced cytotoxicity. *P < 0.05 as compared with control (a) or LiCl 0 + Rot-treated cells (b) (n = 6 in each group)
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as an in vitro model of PD to explore the effects of LiCl 
on rotenone neurotoxicity and its underlying mecha-
nisms. These findings indicated that LiCl could attenu-
ate cell apoptosis, inhibit ROS production and MMP 
decrease induced by rotenone. Moreover, the protective 
effects were partially blocked upon pretreatment with 
autophagy inhibitors such as 3-MA or CHL.
Compared with control group, the ratio of LC3-
II/I was elevated by LiCl treatment, showing that LiCl 
induced autophagy in SH-SY5Y cells. However, this 
autophagy-enhancing effect was partially blocked by 
3-MA, a widely used inhibitor of autophagy. As CHL 
could enhance the cellular burden of autophagosomes 
which were manifested as the accumulation of LC3-II 
protein, the increased ratio of LC3-II/I by chloroquine 
treatment indicated that the maturation of autophago-
somes has been blocked, representing an inhibition of the 
autophagy flux [25].
As a mitochondrial complex I inhibitor, rotenone is 
extensively used for modelling PD in recent years. In this 
study, rotenone induced mitochondrial dysfunction as 
evidenced by the increased production of ROS and the 
decreased MMP, which may lead to the activation of the 
mitochondrial apoptotic pathway [31–33]. Mitochon-
dria have been proposed as an important link among risk 
factors, and eliminating injured mitochondria would be 
Fig. 2 Co-treatment with autophagy inhibitors attenuated neuroprotection of lithium and increased vulnerability of SH-SY5Y to rotenone. Cells 
were pretreated with autophagy-related drugs for 24 h followed by rotenone exposure for another 24 h. The morphology changes of cells were 
shown in (a).The cell viability was measured by MTT assay (b) or Annexin-V/PI staining by flow cytometry (Fig. 3a). *P < 0.05 versus control; #P < 0.05 
versus rot alone; **P < 0.05 as compared with LiCl + Rot group; ##P < 0.05 as compared with LiCl + Rot group (n = 6 in each group)
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critical to prevent cells from a series of pro-apoptotic 
cellular responses. Autophagy is the only process by 
which organelles such as mitochondria can be degraded. 
Previous studies indicated that inhibited autophagy 
was accompanied by accumulated mitochondrial mass 
[34–36]. Thus, we hypothesized that pretreatment 
with autophagy-enhancing agents like LiCl might be 
able to reduce mitochondrial load. As expected, LiCl 
reduced rotenone-induced apoptosis, ROS production 
and MMP reduction, exerting similar neuroprotective 
Fig. 3 Lithium attenuated rotenone-induced dysfunction of mitochondria. Cells were pretreated with autophagy-related drugs for 24 h followed 
by rotenone exposure for another 24 h. The rate of cell apoptosis was measured by Annexin-V/PI staining (a) and the fluorescence intensity of DCFH 
was measured by flow cytometry in all groups (b). MitoTracker red CMXRos at a final concentration of 500 nM was used to visualize the mitochon-
drial transmembrane potential (c) and the relative fluorescence intensity was expressed (d). *P < 0.05 as compared with Con group; #P < 0.05 versus 
Rot alone, **P < 0.05 as compared with LiCl + Rot group; ##P < 0.05 as compared with LiCl + Rot group (n = 6 in each group)
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effects to another autophagy enhancer rapamycin. To 
further investigate whether the neuroprotection of LiCl 
was autophagy-dependent, two chemical suppressors 
of autophagy 3-MA and CHL were used. The converse 
results were observed in cells treated simultaneously 
with 3-MA or CHL, corresponding to the reduced ratio 
of LC3II/I which suggested that the protective effect of 
LiCl could be partially blocked as autophagy was inhib-
ited. Then we observed that the mitochondria fluores-
cence was well merged with the LC3 fluorescence in the 
cytoplasm of LiCl-treated cells when compared to those 
treated with autophagy inhibitors or vehicle control. This 
further supported an elimination of mitochondria via 
autophagy. As the sole known mechanism for mitochon-
drial turnover, autophagy serves to preserve the balance 
between organelle biogenesis and their clearance, and 
engages in cross-talk with mitochondria and oxidative 
stress [37].
Our study have indicated that LiCl alleviated rotenone-
induced cell apoptosis and ROS production through 
autophagy induction, which was consistent with previ-
ous findings that induction of autophagy could protect 
against pro-apoptotic insults by reducing mitochon-
drial load [16, 38, 39]. Scola et al. also found that lithium 
prevented rotenone-induced changes in mitochondrial 
complex I function, cell death and changes to DNA 
methylation and hydroxymethylation [39]. These findings 
let us have a more balanced view on the effects of lithium. 
Since lithium is known to pass the blood–brain barrier 
and has already been approved by FDA for decades for 
the treatment of bipolar disorder [40], we could reason-
ably speculate that by inducing autophagy, lithium may 
have great potential as a novel therapy for PD, although 
the possibility requires further investigation.
Conclusions
Taken together, these findings indicated that lithium was 
able to attenuate cell apoptosis, inhibit ROS production 
and MMP decrease induced by rotenone in SH-SY5Y. 
Moreover, autophagy enhancement was involved in this 
neuroprotection as the effects of lithium were partially 
blocked upon pretreatment with autophagy inhibitors. 
Pharmacologically induction of autophagy by lithium 




Human neuroblastoma SH-SY5Y cells (ATCC, Manassas, 
VA, USA) were cultured in DMEM/F12 medium (Inv-
itrogen, Carlsbad, CA, USA) at 37 °C with 5 % CO2 and 
95  % air (v/v). The growth medium was supplemented 
with 10  % fetal bovine serum (Invitrogen). Rotenone 
(Sigma-Aldrich, St. Louis, MO, USA) and rapamycin 
(Sigma-Aldrich) were dissolved in dimethyl sulfoxide 
(DMSO) before diluted with the culture medium, and 
the final concentration of DMSO per well was less than 
0.2  %. 3-methyladenine (3-MA) (Sigma-Aldrich) was 
dissolved by heating in ddH2O, while LiCl and chloro-
quine (CHL) were dissolved in phosphate buffered solu-
tion (PBS) before dilution with the culture medium. PBS 
and DMSO were added to the culture medium in nega-
tive control group (PBS for 24  h following DMSO for 
another 24  h, “Con-group”). The final concentrations of 
Rap [20, 41], LiCl [20, 42], 3-MA and Chl [20, 43] were 
0.2 μM, 1–50 mM, 10 mM and 10 μM, respectively. Rote-
none (200  nM) was given for 24  h to induce cell dam-
age. For MTT assay, apoptosis analysis, mitochondrial 
membrane potential (MMP) and reactive oxygen species 
(ROS) detection, SH-SY5Y cells were pretreated with 
vehicle (PBS), Rap, LiCl, LiCl  +  3-MA, LiCl  +  CHL, 
3-MA, CHL, respectively, for 24  h, and then rotenone 
for another 24  h. For assessing microtubule associated 
protein 1 light chain 3 (LC3) expression in immunostain-
ing and immunoblotting, the cells were only treated with 
vehicle, Rap, LiCl, LiCl  +  3-MA, LiCl  +  CHL, 3-MA, 
























Fig. 4 Co-treatment with autophagy inhibitors depressed lithium 
induced autophagy in SH-SY5Y cells. The cells were treated with 
autophagy-related drugs at various concentrations for 24 h. The 
induction of autophagy was determined by measuring the LC3 pro-
tein levels using immunoblotting assay with antibody against LC3 (b). 
β-actin was used as an equal loading of proteins. The ratio of LC3B-II/I 
was evaluated by densitometric analysis and data were expressed (a). 
*P < 0.05 as compared with Con group (n = 6 in each group)
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Fig. 5 Lithium promoted degradation of mitochondria via autophagy. Cells exposed to lithium with or without autophagy inhibitors were 
incubated with anti-LC3 antibody (1:100) and MitoTracker Red to visualize the co-localization (yellow immunofluorescence) of LC3 (a–d) and mito-
chondria (e–h) in SH-SY5Y cells at ×400 magnifications under a confocal fluorescence microscope, and the nuclei were stained by DAPI (i–l). The 
co-localization of autophagosomes and mitochondria was marked using white arrows (m–p). The relative intensity of LC3 (q) and mitochondria 
were expressed (r). *P < 0.05 as compared with Con group; **P < 0.05 as compared with LiCl + Rot group; ##P < 0.05 as compared with LiCl + Rot 
group (n = 6 in each group)
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Measurement of cell viability
Cell viability was detected in MTT assay by a micro-
plate reader (Bio-Rad, Hercules, CA, USA) [22, 44, 45]. 
Briefly, SH-SY5Y cells were seeded at a density of 1 × 104 
cells per well in 96-well plates. When exposed to differ-
ent treatments for the indicated times duration, 20 µL 
of MTT solution (5 mg/mL, Sigma-Aldrich) were added 
to each well for 4  h to allow the formation of purple 
formazan crystal. Then, 100 μL of the solubilization rea-
gent was added into each well and spectrophotometri-
cally measured for absorption at λ 570 nm.
Apoptosis analysis
The FITC-conjugated Annexin V (Annexin V, Sigma-
Aldrich) and propidium iodide (PI, Sigma-Aldrich) dou-
ble-staining followed by flow cytometry (BD, Franklin 
Lakes, NJ, USA) assessment was employed to analyze 
the rates of cell apoptosis [22, 44, 45]. Cultivated termi-
nation, 2 × 106 cells were harvested with 0.25 % trypsin 
and washed with PBS, and then incubated with Annexin 
V-FITC (apoptosis detection kit, Sigma-Aldrich) and 
20 μg/mL PI (10 μL) for 10 min at 37 °C in the darkness. 
Then FITC and PI signals were measured with a BD-LSR 
flow cytometer using the CellQuest software. Data were 
analyzed by FSC express version 3.0 (De Novo Software, 
Los Angeles, CA, USA). The apoptosis rate =  [Annexin 
V(+)PI(−) cells  +  Annexin V(+)PI(+) cells]/total 
cell × 100 %.
Measurement of reactive oxygen species
Fluorescent probe 2,7-dichlorofluorescein diacetate 
(H2DCFDA) was used to measure the intracellular ROS 
[22, 44, 45]. The generation of dichlorofluorescein (DCF), 
an oxidized form of H2DCFDA, is proportional to intra-
cellular ROS levels. At the termination of medication, 
cells were harvested, resuspended in PBS and immedi-
ately incubated with 10  μM H2DCFDA (Sigma-Aldrich) 
for 30  min at 37  °C in the darkness. After washed, the 
samples were detected by a FACScan flow Cytometer 
(BD). Data were analyzed by FSC express version 3.0 (De 
Novo Software, Los Angeles, CA, USA).
Detection of mitochondrial membrane potential
Since MitoTracker probe could pass through the plasma 
membrane and accumulate in mitochondria [22, 46], 
assessment of MMP was performed using MitoTracker 
Red CMXRos (Invitrogen). After harvested and resus-
pended with PBS, cells were cultured with MitoTracker 
Red CMXRos (500 nM) for 30 min at 37 °C in the dark-
ness, washed with PBS twice and then the nuclei were 
stained with DAPI (Invitrogen). The MMP level was visu-
alized quantitatively as red fluorescence, while the DNA 
could be simultaneously observed as blue fluorescence.
Autophagy detection in immunoblotting analysis
Autophagy level was detected by a specific marker pro-
tein, the autophagosomal membrane form of microtu-
bule-associated protein 1 light chain 3 (LC3) [5], which 
has two forms, LC3-I (18 KD, a cytoplasmic form) and 
LC3-II (16 KD, a cleavage form). The conversion of LC3-I 
into LC3-II (LC3-II level compared to LC3-I level) was 
indicative of autophagic activity.  Higher ratio of LC3-
II/LC3-I means higher autophagic activity. After har-
vested and washed by cold PBS, cells were directly lysed 
in 100 mL of 2× SDS sample buffer containing protease 
inhibitors and boiled for 5 min [22, 44, 45]. Then total pro-
tein concentration was determined by a BCA kit (Pierce, 
Rockford, IL, USA). Equal amounts of proteins (40  mg) 
were separated by SDS–polyacrylamide gel electrophore-
sis and transferred to polyvinylidene difluoride membrane 
(Pierce). The membranes were then washed three times 
with PBS, blocked with 5  % dry milk in Tris-buffered 
saline for 45 min and incubated with primary antibodies 
directed against LC3 (1: 1000) and β-actin (Santa Cruz, 
Santa Cruz, CA, USA) overnight at 4 °C. Following three 
10-min washes in tris-buffered saline tween-20, the mem-
branes were incubated with the corresponding second-
ary antibody conjugated with HRP at room temperature 
for 1 h. Antibody binding was visualized using enhanced 
chemiluminescence ECL-Plus (Amersham Pharmacia, 
Piscataway, NJ, USA). Blots were quantified using analysis 
system (Quantity One, Hercules, CA, USA).
Visualization of the autophagic degradation 
of mitochondria (mitophagy)
When harvested, SH-SY5Y cells were fixed with 4 % par-
aformaldehyde (Amresco llc, Solon, OH, USA) at 4 °C for 
10 min, washed with PBS and permeabilized with 0.5 % 
Triton X-100 for 2  min, then incubated with primary 
antibody, the monoclonal anti-LC3 antibody (1:100) 
overnight at 4  °C followed by the secondary antibody, a 
fluorescein isothiocyanate conjugated goat anti-rabbit 
antibody (1:60, Sigma-Aldrich) for 2 h at room tempera-
ture. Cells were observed by using a confocal microscope 
(Olympus, Tokyo, Japan) and then images were analyzed 
by Image-Pro Plus 6.0 software package (Bethesda, MD, 
USA) [20].
Statistical analysis
Statistical analyses were carried out using SPSS version 
20.0 for Windows (IBM Corporation, New York, USA). 
All values were expressed as mean ± SD (n = 6 in each 
group). The statistical significance of differences between 
groups was evaluated using a one-way ANOVA followed 
by Fisher’s least significant difference t test, as a normal 
distribution in all groups was given. P value of <0.05 was 
considered as statistically significant.
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